NYMOX PHARMACEUTICAL CORPORATION
NASDAQ : NYMX

NYMOX PHARMACEUTICAL CORPORATION

August 03, 2005 10:01 ET

Tobacco Smoke Exposure for Teens Linked to Obesity and Higher Risk of Cardiovascular Disease and Diabetes

HASBROUCK HEIGHTS, N.J.--(CCNMatthews - Aug 3, 2005) -

Nymox (NASDAQ:NYMX) TobacAlert™ Product Detects Second-Hand Smoke Exposure

A new study has linked exposure to second-hand smoke by teen-agers to metabolic syndrome, a condition associated with obesity and with increased risk of cardiovascular disease, such as stroke and heart attack, and Type II diabetes (Circulation 2005; 112:862-869). The researchers led by Dr. Michael Weitzman of the Center for Child Health Research, University of Rochester School of Medicine and Dentistry, examined data from 2273 subjects aged 12 to 19 from the National Health and Nutrition Examination Survey III and found that teens exposed to second-hand smoke were 4.7 times more likely to have metabolic syndrome and 4.1 times to be seriously obese or at risk for serious obesity than unexposed teens. Actively smoking teens were 6.1 times more likely to have the syndrome and 4.4 times to be seriously obese or at risk for it.

Nymox Pharmaceutical (NASDAQ:NYMX) makes TobacAlert™, an easy-to-use, cost-effective product that allows for on-site testing for second-hand smoke exposure. TobacAlert™ can be used at home, at school or in the workplace. No instruments are required and results are provided within minutes.

"The evidence of the risks posed by second-hand smoke exposure to children and adolescents continues to mount," said Brian Doyle, Nymox's Manager of Global Sales and Marketing. "People are often unaware of the nature and extent of second-hand smoke exposure, both to themselves and to their family. TobacAlert™ offers a convenient and easy way to get some objective answers."

TobacAlert™ is available at over 5,400 CVS/pharmacy® stores across the U.S. as well as online at www.cvs.com. More information is available at www.tobacalert.com.

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.

Contact Information

  • Nymox Pharmaceutical Corporation
    Roy Wolvin, 1-800-93NYMOX
    www.nymox.com